GTBP:NASDAQGT Biopharma, Inc. Analysis
Data as of 2026-08-20 - not real-time
$0.28
Latest Price
9/10Risk
Risk Level: High
Executive Summary
The moving-average structure behind GT Biopharma, Inc. is bearish at $0.2820, with short-term averages lagging the long-term ones. It has lost 36.9% over the past 30 days. RSI sits at 37.0, which reads as approaching oversold, and MACD momentum is bullish. Recent trading has carved out support near $0.2690 and resistance around $0.3500.
On valuation the read is undervalued — earnings multiple of 0.1 versus a 30.7 sector average, below the peer group. Analyst price targets sit 963.8% above the current price.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 71.8%, a beta of 1.91 and a maximum drawdown of 76.1%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 1/10.
On valuation the read is undervalued — earnings multiple of 0.1 versus a 30.7 sector average, below the peer group. Analyst price targets sit 963.8% above the current price.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 71.8%, a beta of 1.91 and a maximum drawdown of 76.1%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 1/10.
Top Market Events
GT Biopharma GTBP witnesses a hammer chart pattern, indicating support found by the stock after losing some value...TMCnet6dGT Biopharma Reports Second Quarter 2026 Financial ResultsPhase 1 basket trial evaluating GTB-5550 TriKE ® in...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 0.50
- MACD momentum is positive
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked below long-term ones
- P/E of 0.1 versus sector average of 30.7
- Trading below the 200-day average of 0.50
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- P/E of 0.1 versus sector average of 30.7
- Analyst targets imply +963.8% versus the current price
- Negative return on equity of -113.5%
Key Metrics & Analysis
Financial Health
P/E Ratio0.1
ROE-113.52%
ROA-158.16%
P/B Ratio3.5
Op. Cash Flow$-14426000
Free Cash Flow$-8957375
Industry P/E30.7
Technical Analysis
TrendBearish
RSI37.0
Support$0.27
Resistance$0.35
MA 20$0.31
MA 50$0.38
MA 200$0.50
MACDBullish
VolumeStable
Fear & Greed Index92.84
Valuation
Target Price$3.00
Upside/Downside963.83%
GradeUndervalued
TypeBlend
Risk Assessment
Beta1.91
Volatility71.78%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.